Ghosn 2005.

Methods	REVERSE study N=23 Non randomized FUP=24 weeks w/o d/o=unclear
Participants	Eligibilty:‐ VL>30,000 copies/ml, ART>3 drugs, Mutations: 1.3TAM+1NNRTI+2PI Baseline mutations: 17(9‐28) Baseline CD4:43(1‐372) Baseline VL 5.14(4.51‐5.69)
Interventions	24 wks TI (12‐37 wks)
Outcomes	STI arm: CD4 decline: no significant decline Viral rebound: no significant rebound Viral reversion: 70% patients Drug susceptibility : Increased in 16/23 participants
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	D ‐ Not used